The uncertain future of TikTok and the changing social media landscape has made complicated partnerships and engagement measurement in the creator economy. But creators are ready.

Temu burst onto the US retail scene in September 2022, winning over shoppers with ultra-low prices and aggressive ad campaigns. But while its initial growth was fueled by new customers, its long-term success is now driven by repeat buyers.

Snapchat enhances brand safety features: The changes stand in contrast with Meta scaling back its brand safety commitments.

Lawmakers pressure Amazon into improving ad transparency: A bipartisan letter stemming from Adalytics highlighted quality issues with DSPs.

It reminded consumers how volatile the industry can be, deepening distrust that will be a major hurdle to overcome

Facing global trade tensions, Apple is pumping billions into US-based production—potentially sweetening the deal for future tariff exemptions.

In-Jeep ad pop-ups demonstrate how automakers want revenue from connected cars, but aggressive tactics could push drivers to reject paid features altogether

Home Depot expects sales to grow 2.8% this year: While the housing market is unlikely to thaw, the home improvement retailer sees signs that consumers will stop putting off projects.

Ecommerce penetration of beauty and personal care sales is rising: 41% of category sales take place on platforms like Amazon and TikTok Shop as consumers respond to virality and convenience.

Unilever is unhappy with turnaround progress: The CPG company abruptly replaced CEO Hein Schumacher as it pushes for a faster recovery.

Warehouse club membership has its privileges: Strong sales show that consumers see these stores as a smart way to save as costs rise.

US docs spend up to 3 hours per week correcting AI: Physicians’ liability concerns with AI can be addressed by having them involved with technology purchasing decisions.

Only 18% of consumers have ever asked their doctor about a drug ad: But when they do, many patients walk away with a prescription for that medication. We explore how pharma marketers can get the most out of their ad campaigns.

Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.